| 459 | For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)). |
| | LU Authorization Period: Indefinite. |
| | NOTE: COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).
Classification
COPD Stages - Symptoms and disability:
Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.
Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level
Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure
Classification by impairment of lung function:
COPD stage and spirometry (post bronchodilator) FEV1 predicted:
Mild: Greater than or equal to 80 percent
Moderate: 50 to 79 percent
Severe: 30 to 49 percent
Very severe: Less than 30 percent
|
